Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

24.61 +0.31 (+1.28%)
Official Closing Price Updated: 7:00 PM EST, Nov 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Novo Nordisk Snaps 11-Day Losing Streak After Court Rejects Pfizer’s Challenge To $10B Metsera Deal
Delaware Chancery Judge Morgan Zurn ruled that Pfizer’s objections did not justify delaying Novo’s $10 billion acquisition of obesity-drug startup Metsera. 
Via Stocktwits
Topics Law Enforcement
US Economic Resilience Fuels Dollar's Ascent Amidst Global Shifts
The United States economy is currently riding a wave of positive momentum, with a series of robust economic indicators signaling underlying strength and resilience. This optimistic outlook has, in... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
Pfizer Responds to Delaware Chancery Court Ruling
From Pfizer Inc.
Via Business Wire
Eli Lilly And Novo Nordisk Ignite Bullish Retail Frenzy Ahead Of TrumpRx Deals To Slash Prices For Weight-Loss Drugs
Via Stocktwits
Navigating the Tempest: Market Consolidation Amidst Post-Slide Uncertainty
The financial markets, still reeling from a tumultuous period marked by significant downturns, are now grappling with an uneasy attempt at consolidation. As of November 5, 2025, investors are... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
Obesity Drugmakers Face Shifting Tides: Novo Nordisk Plunges While Eli Lilly Soars
The burgeoning market for obesity and diabetes treatments, particularly GLP-1 receptor agonists, is witnessing a dramatic divergence in fortunes among its leading players. As of November 5, 2025, Novo... 
Via MarketMinute
Topics Economy
US Government Shutdown Casts a Shadow: Data Blackout and Market Jitters as Longest Shutdown Unfolds
The United States finds itself in an unprecedented economic fog as a prolonged government shutdown, now stretching well into its second month, has brought the flow of critical official data to a... 
Via MarketMinute
Topics Economy
These S&P500 stocks are the most active in today's session
Stay informed about the most active S&P500 stocks in today's session as we take a closer look at what's happening on the US markets on Wednesday. Discover the stocks that are generating the highest... 
Via Chartmill
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
AI Achieves Atomic Precision in Antibody Design: A New Era for Drug Discovery Dawns
Seattle, WA – November 5, 2025 – In a monumental leap for biotechnology and artificial intelligence, Nobel Laureate David Baker’s lab at the University of Washington’s Institute for Protein Design... 
Via TokenRing AI
Topics Artificial Intelligence Intellectual Property
Here's Why Shares in Viking Therapeutics Shot Higher in October
Three factors took Viking's shares higher in the month. 
Via The Motley Fool
3 Magnificent Ultra-High-Yield Dividend Stocks -- Sporting an Average Yield of 8.5% -- to Buy With Confidence in November
These supercharged income stocks have the necessary catalysts to pad the pocketbooks of patient investors. 
Via The Motley Fool
U.S. Government Shutdown Plunges Nation into Uncharted Economic Waters: Longest in History Deepens Market Uncertainty
Washington D.C., November 5, 2025 – The United States is grappling with an unprecedented fiscal crisis, as an ongoing government shutdown, now in its 36th day, has officially become the longest in the... 
Via MarketMinute
Topics Bonds Economy Government
Can Novo Nordisk’s ‘Attractive’ Fundamentals Outweigh Slowing Wegovy Sales And A $149 Price Cap?
Novo Nordisk cut its 2025 profit and sales forecasts as slower GLP-1 growth and pricing pressure hit margins. 
Via Stocktwits
Topics Lawsuit
PFE Q3 Deep Dive: Pipeline, Cost Controls, and Business Development Shape Outlook
Global pharmaceutical company Pfizer (NYSE:PFE) met Wall Streets revenue expectations in Q3 CY2025, but sales fell by 5.9% year on year to $16.65 billion. On the other hand, the company’s full-year... 
Via StockStory
U.S. PMI Data Looms: A Pivotal Moment for the Dollar and Global Markets
The financial world is holding its breath as the release of the upcoming U.S. Purchasing Managers' Index (PMI) data draws near. This crucial economic indicator is not merely a snapshot of business... 
Via MarketMinute
Topics Bonds Economy Supply Chain
AI Unleashes a New Era in Cell and Gene Therapy: A Quarter Century Update Reveals Transformative Potential
The burgeoning fields of cell and gene therapy (CGT) are on the cusp of a profound revolution, driven by the relentless advancements in artificial intelligence. This transformative impact was a central... 
Via TokenRing AI
Topics Artificial Intelligence
Precious Metals Under Pressure: Dollar Rallies, Stocks Retreat, and Rate Outlook Weighs Heavily
As of November 4, 2025, the global financial markets are witnessing a significant shift, with a rallying US dollar and a retreating stock market exerting considerable downward pressure on gold and... 
Via MarketMinute
Topics Economy Stocks Supply Chain
Novo, Pfizer Are Battling To Buy The Future Of Weight-Loss — But Viking Already Owns It
Viking Global's $45 million investment in Metsera, a biotech company is caught in a bidding war between Pfizer and Novo Nordisk. 
Via Benzinga
Pfizer, Novo Nordisk Intensify Fight For Metsera As Buyout Offers Continue To Climb
Novo Nordisk boosts its Metsera bid to $62.20 per share, valuing the company at $10 billion and outbidding Pfizer in the escalating takeover fight. 
Via Benzinga
Curious about the most active S&P500 stocks in today's session?
Stay informed about the most active stocks in the S&P500 index on Tuesday's session. Discover the stocks that are generating the highest trading volume and driving market activity. 
Via Chartmill
Most active stocks in Tuesday's session
Let's have a look at what is happening on the US markets on Tuesday. Below you can find the most active stocks in today's session. 
Via Chartmill
Pfizer Q3 Revenue Trends Remain Uneven, Cost Cuts Drive Earnings
Pfizer revenue trends remained uneven in the third quarter, the company exhibited "continued cost discipline," according to Goldman Sachs. 
Via Benzinga
These S&P500 stocks have an unusual volume in today's session
In today's session, there are S&P500 stocks with remarkable trading volume. Explore the stocks exhibiting unusual volume in Tuesday's session. 
Via Chartmill
Palantir Weighs On Wall Street, Bitcoin Slumps 5%: What's Moving Markets Tuesday?
Risk appetite cooled on Tuesday as investors interpreted the latest batch of corporate earnings as solid but not spectacular, offering a convenient excuse to take profits after strong year-to-date... 
Via Benzinga
Pfizer (PFE) Q3 2025 Earnings Call Transcript
Pfizer (PFE) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
Novo Sweetens Its Bid For Metsera, Pledging Up To $10 Billion
Novo Nordisk said it would pay up to $10 billion to acquire obesity-focused Metsera, topping Pfizer's recently hiked bid. 
Via Investor's Business Daily
Dow Dips Over 400 Points; Pfizer Earnings Top Estimates
 
Via Benzinga
Topics Stocks
Metsera Gets Revised Bids From Pfizer, Novo Nordisk: Here’s Why It Matters
Metsera said that it would be entitled to terminate its merger agreement with Pfizer if Novo’s proposal continues to be superior. 
Via Stocktwits
Pfizer's Core Drugs Offset COVID Revenue Drop, Lifts 2025 Profit Outlook Despite Tariffs
Pfizer beat Q3 estimates with 87 cents EPS, raised 2025 profit guidance, as Eliquis and Vyndaqel growth offset declining COVID product sales. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.